Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast by Zhang, Zhenhuan et al.
R250
Introduction
It is well established that estrogens are important for the
growth and development of normal mammary gland, as
well as for the initiation and progression of estrogen-
dependent breast cancer. The effect of estrogens on
breast tumorigenesis is believed to be mediated mainly
through estrogen receptor (ER)-α. Breast cancer occurs
more frequently in postmenopausal women than in
younger women, and a higher proportion of these older
patients have tumors that are sensitive to hormones. In
postmenopausal women the concentration of estradiol in
breast cancer tissue is reported to be higher than in
plasma and normal breast tissue [1]. The high concentra-
tion of estradiol in breast cancer tissues of post-
menopausal women may be due to in situ synthesis of
estrogen by breast tissues, which is believed to be cat-
alyzed mainly by aromatase [2]. Reports of the contribu-
tion to in situ estrogen production by stromal cells as
opposed to that by breast cancer cells, assessed immuno-
histochemically, are controversial [3–12]. Some previous
ER = estrogen receptor; PgR = progesterone receptor; RT-PCR = reverse transcription polymerase chain reaction.
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Abstract
Background: Estrogen is a mitogenic factor that is implicated in
the genesis and progression of breast cancer via its binding to
estrogen receptor (ER)-α. Synthesis of estrogen in situ is
believed to be catalyzed mainly by aromatase. Previous studies
comparing the relative contributions from tumor cells and
stromal cells to local estrogen synthesis, as assessed by
immunohistochemical analysis, were quite controversial and no
consistent relationship was found between the presence of
aromatase and any clinicopathologic factor. In addition, previous
studies into aromatase gene expression and clinicopathologic
factors are limited.
Methods: We assessed the level of expression of aromatase
mRNA, using quantitative real-time RT-PCR, in 162 cases of
invasive ductal carcinoma of the breast. Associations between
aromatase expression and different clinicopathologic factors
were sought.
Results: It was found that aromatase mRNA was expressed at
significantly higher levels in patients older than 50 years, in
those without axillary lymph node involvement, in those with
tumor size less than 2cm, and in ER-α positive tumors.
However, no relationship was found between aromatase mRNA
expression and any other clinicopathologic factor, including
histologic grade and progesterone receptor status. Patients
with high levels of expression of aromatase mRNA tended to
have a better prognosis than did those patients with low
expression.
Conclusion: These findings imply that ER-α and aromatase
may be coexpressed in endocrine responsive patients. They
may also indicate that aromatase expression could be a marker
of endocrine responsiveness, and it may have prognostic
implications for breast cancer progression.
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studies showed no consistent relationship between ER-α
status and tumor aromatase levels by immunohistochem-
istry [3,4,8,12].
The human aromatase gene, CYP19 [13], yields an mRNA
that spans nine exons with the translation start site begin-
ning at exon II [14,15]. Its transcription is regulated in a
tissue-specific manner [16–19]. However, studies of
associations between aromatase gene expression and
clinicopathologic factors in breast cancer have been
limited and the results discordant. In the present study,
using quantitative real-time LightCycler RT-PCR (Roche
Molecular Biochemicals, Mannheim, Germany), we corre-
lated aromatase mRNA expression with other clinico-
pathologic factors in 162 cases of invasive ductal
carcinoma of the breast.
Materials and methods
Patients and sample
A total of 162 primary invasive ductal breast carcinoma
specimens were obtained by surgical excision at the
Department of Breast and Endocrine Surgery, Nagoya
City University Medical School, Nagoya, Japan between
1992 and 2000. The research protocol for the study was
approved by the ethics committee of Nagoya City Univer-
sity Graduate School of Medicine, Nagoya, and informed
consent was obtained from all patients before surgery.
Stage I patients without nodal metastasis did not receive
any adjuvant therapy. Most of the stage II and III patients,
who were ER-positive and/or progesterone receptor
(PgR)-positive, received adjuvant endocrine therapy using
tamoxifen (20mg/day, orally) for 5 years. The median age
of the patients was 53 years (range 34–88 years), and all
patients were women.
Patients were followed postoperatively every 3 months by
clinical and radiologic examination. The median follow-up
period was 58 months (range 22–90 months). Patients
were graded histopathologically according to the modified
Bloom and Richardson method proposed by Elston and
Ellis [20]. Samples were snap frozen in liquid nitrogen and
stored at –80°C until RNA extraction.
Total RNA isolation and reverse transcription
Total RNA from microscopically confirmed homogeneous
breast cancer tissue was isolated from approximately
500mg of frozen specimen or from one flask of the
HepG2 cell line, kindly provided by Dr N Harada [21], as a
positive control and to generate standard curves. mRNA
was isolated using the Trizol reagent (Life Technologies
Inc., Tokyo, Japan) according to the manufacturer’s
instructions. RT reactions were performed as previously
described [22]. Briefly, each 20µl cDNA synthesis mixture
contained 1µg total RNA, buffer (10mmol/l Tris-HCI [pH
9.0], 50mmol/l KCI, 1.5mmol/l MgCI2), 1mmol/l each of
deoxynucleotide triphosphates, 25 units of RNA-guard
RNase inhibitor (Amersham Pharmacia Biotech Inc.,
Tokyo, Japan), 200 units of Superscript II reverse tran-
scriptase (Life Technologies Inc.), and 100ng pd(N)6
random hexamer (Amersham Pharmacia Biotech Inc.).
Primers and probes
We conducted Blast searches (GenBank) to confirm the
specificity of the nucleotide sequences chosen for the
primers and probes, and to confirm the absence of DNA
polymorphism. To avoid detection of contaminating
genomic DNA, the primers were located at exons 3 and 4.
The specific oligonucleotide primers were synthesized
according to published information on the aromatase gene
[23] as follows: sense primer 5′-TCT GGA TCT CTG
GAG AGG AAA-3’ (384–404); and antisense primer
5′-GCC TTT CTC ATG CAT ACC GA-3′ (517–498). The
PCR product size is 140 base pairs. The donor probe
5′-CTG CCG AAT CGA GAG CTG TAA TGA TT-3′ has a
fluorescein label at its 3′ end. The acceptor probe 5′-TGC
TTC ATT ATG TGG AAC ATA CTT GAG GAC-3′ has LC
Red 640 at its 5′ end.
To ensure the fidelity of mRNA extraction and reverse tran-
scription, all samples were subjected to PCR amplification
with oligonucleotide primers and probes specific for the
constitutively expressed glyceraldehyde-3-phosphate
dehydrogenase gene (GAPDH) and normalized. GAPDH
primers were as follows: forward primer 5′-AAA TCA AGT
GGG GCG ATG CTG-3′; and reverse primer 5′-GCA
GAG ATG ATG ACC CTT TTG-3′. The sequences of the
GAPDH probes used for real-time LightCycler PCR were
5′-AGA AGG CTG GGG CTC ATT TGC AGG G-3′ and
5′-GTC CAC TGG CGT CTT CAC CAC CAT G-3′. All
primers and probes were purchased from the Japanese
Gene Institute (Saitama, Japan).
Real-time reverse transcription polymerase chain reaction
PCR was performed using a LightCycler. The PCR reac-
tion was carried out in a 20µl final volume containing the
following: H2O up to 20µl; 2.4µl 25mmol/l MgCl2; 0.5µl
20pmol/µl sense primer and antisense primer; 0.4µl
10pmol/µl donor and acceptor probe; 2µl PCR master
mix; and 1.5µl cDNA. After an initial denaturation step at
95°C for 60s, temperature cycling was initiated. Each
cycle consisted of denaturation at 95°C for 0s, hybridiza-
tion at 56°C for 5s, and elongation at 72°C for 6s. The
fluorescence signal was acquired at the end of the
hybridization step. A total of 55 cycles were performed.
Cycling conditions for GAPDH  were as follows: initial
denaturation at 95°C for 60s, followed by 50 cycles at
95°C for 0s, 60°C for 5s, and 72°C for 8s.
Standard curves and expression of results
For each PCR run, a standard curve was constructed from
serial dilutions of cDNA from the HepG2 cell line. The levelBreast Cancer Research    Vol 5 No 6 Zhang et al.
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of expression of aromatase mRNA is given as relative copy
numbers normalized against GAPDH mRNA and shown as
mean±standard deviation. Relative aromatase mRNA
expression was calculated using the formula (A/G) ×1000,
where A is the relative copy numbers of aromatase mRNA
and G is the relative copy numbers of GADPH mRNA.
A nontemplate control was included in each experiment.
All of the nontemplate controls, the standard cDNA dilu-
tions from the HepG2 cell line, and the tumor samples
were assayed in duplicate. All of the patient samples with
a coefficient of variation for gene mRNA copy number
data greater than 10% were retested using the method of
Bieche and coworkers [24].
Immunohistochemical staining of estrogen receptor-α α
and progesterone receptor
Immunostaining of ER-α and PgR was performed as previ-
ously described [25]. Briefly, the slides were incubated
with anti-ER-α primary antibody (ER1D5; Dako, Kyoto,
Japan) at a 1:100 dilution or anti-PgR primary antibody
(PgR636; Dako), also at a 1:100 dilution, using the strep-
tavidin–biotin system (SAB-PO kit; Nichirei, Tokyo, Japan)
according to the manufacturer’s instructions. The
immunostaining of ER-α and PgR was subjectively
assessed by two independent investigators (ZZ and HI),
and discordant results were resolved by consultation with
a third investigator (HY), as previously described [26].
Expression of ER-α and PgR was scored by assigning a
proportion score and an intensity score according to
Allred’s procedure [27]. In brief, the proportion of positive
staining throughout the entire slide was assessed as 0
(negative), 1 (<1%), 2 (1–10%), 3 (10–33%), 4
(33–66%) and 5 (>66%), and the average staining inten-
sity was recorded as 0 (negative), 1 (weak), 2 (moderate),
or 3 (strong) under light microscopy. The immunohisto-
chemistry score for each slide (0 or 2–8) was obtained as
the sum of the proportion and intensity. ER-α and PgR
status by immunohistochemistry was then assessed as
negative (score 0–2) or positive (score 3–8).
Statistical analysis
The nonparametric Mann–Whitney U-test was used for
statistical analysis of associations between aromatase
expression and clinicopathologic factors. Disease free sur-
vival curves were generated using the Kaplan–Meier
method and verified using log-rank (Mantel–Cox) and
Breslow–Gehan–Wilcoxon tests. P<0.05 was consid-
ered statistically significant.
Results
Characteristics of the patients
Clinical characteristics are summarized in Table 1. Of the
162 patients with invasive ductal carcinoma that we exam-
ined, 104 patients were older and 58 were younger than
50 years, respectively; and 59 had axillary lymph node
metastases, whereas 103 had no metastases; and in
43 cases the tumor was less than 2cm and in 119 cases
it was more than 2cm in size. By ER-α immunohistochem-
istry, in 108 cases the tumor was ER-α positive, in
47 cases the tumor was ER-α negative, and in seven
cases the ER-α status could not be determined. In com-
parison, immunohistochemical analysis revealed that in
87 cases the tumor was PgR positive, in 62 cases the
tumor was PgR negative, and in 13 cases the PgR status
could not be determined. The tumor was classified as not
being high grade in 113 patients, whereas in 49 cases
histologically high-grade tumor was present. The amount
of aromatase mRNA in the 162 cases ranged from 0 to
486, with a median of 24 relative copy numbers.
Level of expression of aromatase mRNA correlates with
age, axillary lymph node metastasis, and tumor size
The level of aromatase mRNA expression in the group of
patients older than 50 years of age (29±60) was signifi-
cantly greater than that in the patients younger than
50 years (14±24, P=0.0042; Fig.1a). The expression in
patients lacking axillary lymph node metastases (30±62)
was significantly higher than that in the group with axillary
lymph node metastases (13±20, P=0.010; Fig.1b). In
addition, it was found that the level of aromatase mRNA
expression in the group with tumors less than 2cm
(29±54) was greater than that in the group with tumors
larger than 2cm (22±50, P=0.042; Fig.1c).
Table 1
Aromatase mRNA expression and clinicopathologic factors in
patients with invasive ductal carcinoma
Aromatase mRNA P
(mean± standard   (Mann–Whitney 
Factor n deviation) U-test)
Age (years)
>50 104 29±60 0.0042*
≤50 58 14±24
Axillary lymph node status
– 103 30±62 0.010*
+ 59 13±20
Tumor size
<2cm 43 29±54 0.042*
≥2cm 119 22±50
ER-α status
+ 108 28±59 0.0021*
– 47 13±20
PgR status
+ 87 24±44 0.63
– 62 25±63
Histologic grade
1 or 2 113 24±50 0.11
3 49 24±54
Estrogen receptor (ER)-α status and progesterone receptor (PgR)
status were determined histochemically. *P<0.05.Level of expression of aromatase mRNA correlates with
immunohistochemically determined esterogen
receptor-α α protein expression
The level of aromatase mRNA expression was also found
to be higher in the immunohistochemically determined
ER-α positive group (28±59) than that in the negative
group (13±20, P=0.0021; Fig.1d). However, there was
no difference in the level of aromatase mRNA expression
between the PgR positive and negative groups by
immunohistochemical PgR detection. We also analyzed
aromatase mRNA expression in the subgroups of women
who were premenopausal and postmenopausal, but we
did not find any significant correlation (data not shown),
which was probably due to the small number of individuals
in the subgroups.
The level of expression of aromatase mRNA and other
clinicopathologic factors and prognosis
The level of aromatase mRNA expression was not found to
be significantly correlated with any other clinicopathologic
factor, including histologic grade (Table 1). To identify a
cutoff point for aromatase mRNA expression that is clini-
cally meaningful with respect to prognosis, various levels
of aromatase mRNA expression were tested using the
Kaplan–Meier method and verified using log-rank (Mantel–
Cox) and Breslow–Gehan–Wilcoxon tests. When the cutoff
point of aromatase mRNA level was set at 10, patients with
high level aromatase mRNA expression (46±68, n=77)
tended to have a better prognosis than did those with low
expression (4±3, n=85; log-rank test P=0.073; Breslow–




Comparison of aromatase mRNA expression between the following groups: (a) patients older than and those younger than 50 years of age; (b)
patients who were negative and those who were positive for lymph node metastasis; (c) patients with tumor size <2cm and those with tumor size
≥2cm; and (d) patients who were estrogen receptor (ER)-α positive and those who were ER-α negative, by histochemistry. The boxes represent
the mean and the 70% confidence intervals; bars are standard deviations. The aromatase mRNA expression was significantly greater in those older
than 50 years (29±60) than in those younger than 50 years (14±24; P=0.0042). It was significantly greater in samples negative for lymph node
metastasis (30±62) than in samples positive for lymph node metastasis (13±20; P=0.010). The aromatase mRNA expression was significantly
greater in the group with tumor size <2cm (29±54) than in the group with tumor size ≥2cm (22±50; P=0.042). Finally, it was significantly
greater in the ER-α positive group (28±59) than in the ER-α negative group (13±20; P=0.0021).Discussion
The mitogenic activity of estrogens in the promotion and
progression of estrogen responsive breast cancer is well
established, and is mediated mainly via ER-α. In situ estro-
gen synthesis catalyzed by aromatase plays an important
role in breast cancer, especially in postmenopausal
patients, whose ovarian function has ceased. The final,
rate limiting step in estrogen biosynthesis is controlled by
the cytochrome P450-type enzyme complex aromatase.
Previous studies of the immunohistochemical localization
of aromatase in breast cancer have been controversial.
Some studies utilizing either monoclonal [6,8] or poly-
clonal antibodies [5,12] localized aromatase mainly to the
tumor cells. However, other studies that utilized polyclonal
antibodies [7,10,11] reported that aromatase was mainly
detectable in the stromal cells. Our previously published
results are consistent with those studies that reported
positive cytoplasmic staining in both stromal and tumor
cells [26].
Previous studies concerning the detection of aromatase
expression by immunohistochemistry and its association
with clinicopathologic factors, especially with ER-α, failed
to produce consistent results. Esteban and coworkers [3]
first detected aromatase immunoreactivity using a specific
polyclonal antibody against human placental aromatase in
the cytoplasm of carcinoma cells; they showed a signifi-
cant, but inverse, correlation between aromatase activity
and the ER-α status (P=0.04). This indicated increased
likelihood of negative estrogen status if substantial aro-
matase activity was present [3]. In a study conducted by
Sasano and coworkers [4], aromatase immunoreactivity in
the stromal cells and/or adipocytes of breast cancer tissue
was not always observed in cells adjacent to ER-α and
PgR positive carcinoma cells, including cases in which
ER-α, PgR, and aromatase were detected in the same
specimens. Brodie and coworkers [12] reported that
tumors with relatively high aromatase activity tend to be
ER-α positive; six out of nine ER positive tumors
expressed aromatase, whereas six out of 10 ER negative
tumors lacked aromatase. Miller and coworkers [28] also
observed a significant trend toward an association
between aromatase activity and the presence of ER-α,
although tumors expressing active aromatase included
both ER-α positive and negative tumors. It is difficult to
postulate a role for estrogens produced in situ in tumors
that lack ERs [8]. Our previous studies showed that the
level of aromatase expression was not correlated with
ER-α and PgR, as detected by immunohistochemistry, or
with any other clinicopathologic factors including age,
tumor size, axillary lymph node involvement and histologic
grade, either in tumor cells or in stromal cells [26].
Because of the above discrepancies, we felt that investi-
gating aromatase gene expression could shed light on the
functional significance of aromatase in breast cancer.
Earlier studies of aromatase mRNA expression in breast
cancer are limited. It was reported that levels of aromatase
mRNA were highest in a tumor bearing quadrant [29], and
were significantly higher than in those regions distal to the
tumor or in nonmalignant breast tissue [30]. The presence
of aromatase mRNA was found to correlate with enzyme
activity [31]. However, one study [32] indicated that,
although there is a positive correlation between aromatase
transcript levels and enzyme activity, this failed to achieve
statistical significance. Therefore, whereas aromatase
mRNA quantification may be an option for monitoring the
potential of tumor tissue to synthesize estrogens, it may
not accurately reflect enzyme activity in a minority of
tumors. In the present study it was found that aromatase
mRNA expression was significantly greater in ER-α posi-
tive than in ER-α negative patients. This finding is not con-
sistent with earlier studies that failed to show a
relationship between aromatase mRNA levels and ER-α
[33,34]. The discrepancy may be due to differences in the
methodology applied to detect ER-α. In one earlier study
[33] ER-α protein levels in breast cancer were assessed
by enzyme immunoassays, and in another study [34] ER-α
protein levels in breast cancer were assessed using
dextran coated charcoal method until 1988 and enzyme
immunoassay thereafter. In the present study, however,
immunohistochemical methodology was employed.
Another reason for the discrepancy between studies
regarding the relationship of ER-α with aromatase mRNA
level may be that aromatase is distributed mainly in tumor
cells or stromal cells, but this is controversial.
The higher level of aromatase mRNA expression in
patients older than 50 years and with tumor size less than
2cm, but who are ER-α positive and axillary lymph node
Breast Cancer Research    Vol 5 No 6 Zhang et al.
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Figure 2
Statistical analysis of aromatase mRNA expression levels and disease
free survival, using the Kaplan–Meier method. The patients with high
aromatase mRNA expression in their tumors (46±68) exhibited a trend
toward better prognosis than did those with lower expression (4±3;
log-rank [Mantel–Cox] test P=0.073; Breslow–Gehan–Wilcoxon test
P=0.035).negative (taken together with a previous study [33] that
documented higher aromatase mRNA expression in the
group negative for lymph node metastasis group) may
imply that ER-α and aromatase may be coexpressed in
endocrine responsive patients. This may further suggest
that aromatase gene expression could be a potential
endocrine responsiveness marker and may have prognos-
tic significance in breast cancer.
Conclusion
Despite the limited number of patients involved in this
study (only 162 cases), the significant correlation between
aromatase mRNA expression and age over 50 years, neg-
ative lymph node metastasis, smaller tumor size, ER-α
positive status, and better prognosis imply that ER-α and
aromatase may be coexpressed in endocrine responsive
patients. Our findings also indicate that aromatase gene
expression is a potential marker of endocrine responsive-
ness and may have prognostic significance in breast
cancer. Further studies, including a larger number of
cases, microdissected breast tumor tissue, and longer
periods of follow up, are warranted to elucidate the func-
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